Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms.

Previous randomized controlled trials suggest that using clinical algorithms based on procalcitonin levels, a marker of bacterial infections, results in reduced antibiotic use without a deleterious effect on clinical outcomes. However, algorithms differed among trials and were embedded primarily within the European health care setting. Herein, we summarize the design, efficacy, and safety of previous randomized controlled trials and propose adapted algorithms for US settings. We performed a systematic search and included all 14 randomized controlled trials (N = 4467 patients) that investigated procalcitonin algorithms for antibiotic treatment decisions in adult patients with respiratory tract infections and sepsis from primary care, emergency department (ED), and intensive care unit settings. We found no significant difference in mortality between procalcitonin-treated and control patients overall (odds ratio, 0.91; 95% confidence interval, 0.73-1.14) or in primary care (0.13; 0-6.64), ED (0.95; 0.67-1.36), and intensive care unit (0.89; 0.66-1.20) settings individually. A consistent reduction was observed in antibiotic prescription and/or duration of therapy, mainly owing to lower prescribing rates in low-acuity primary care and ED patients, and shorter duration of therapy in moderate- and high-acuity ED and intensive care unit patients. Measurement of procalcitonin levels for antibiotic decisions in patients with respiratory tract infections and sepsis appears to reduce antibiotic exposure without worsening the mortality rate. We propose specific procalcitonin algorithms for low-, moderate-, and high-acuity patients as a basis for future trials aiming at reducing antibiotic overconsumption.

[1]  D. Heyland,et al.  Procalcitonin for reduced antibiotic exposure in the critical care setting: A systematic review and an economic evaluation* , 2011, Critical care medicine.

[2]  V. Luther,et al.  Antimicrobial stewardship for inpatient facilities. , 2011, Journal of hospital medicine.

[3]  E. Ruokonen,et al.  Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study , 2010, Critical care.

[4]  A. Armaganidis,et al.  Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: A systematic review and meta-analysis of randomized controlled trials , 2010, Critical care medicine.

[5]  Xi-rong Guo,et al.  The accuracy of the procalcitonin test for the diagnosis of neonatal sepsis: A meta-analysis , 2010, Scandinavian journal of infectious diseases.

[6]  Mirjam Christ-Crain,et al.  Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. , 2010, Chest.

[7]  T. Welte,et al.  Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection , 2010, European Respiratory Journal.

[8]  F. Tubach,et al.  Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial , 2010, The Lancet.

[9]  Bala Hota,et al.  Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  W. Cui,et al.  Effect of Procalcitonin-Guided Treatment in Patients with Infections: a Systematic Review and Meta-Analysis , 2009, Infection.

[11]  S. Marsch,et al.  Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study , 2009, European Respiratory Journal.

[12]  M. Fine,et al.  Measurement of serum procalcitonin: a step closer to tailored care for respiratory infections? , 2009, JAMA.

[13]  T. Bregenzer,et al.  Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. , 2009, JAMA.

[14]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[15]  M. Christ-Crain,et al.  Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype? , 2009, Swiss medical weekly.

[16]  B. Bein,et al.  Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial , 2009, Critical care.

[17]  M. Sodemann,et al.  Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission--a randomized trial. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[18]  Jianguo Tang,et al.  [The value of serum procalcitonin in treatment of community acquired pneumonia in outpatient]. , 2009, Zhonghua nei ke za zhi.

[19]  B. Bein,et al.  Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study , 2009, Langenbeck's Archives of Surgery.

[20]  M. Briel,et al.  Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. , 2008, Archives of internal medicine.

[21]  D. Altman,et al.  Assessing Risk of Bias in Included Studies , 2008 .

[22]  J. Pugin,et al.  Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. , 2008, American journal of respiratory and critical care medicine.

[23]  J. Kline,et al.  Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. , 2007, Annals of emergency medicine.

[24]  P. Svoboda,et al.  Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery? , 2007, Hepato-gastroenterology.

[25]  Anthony S McLean,et al.  Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. , 2007, The Lancet. Infectious diseases.

[26]  M. Christ-Crain,et al.  Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. , 2007, Chest.

[27]  M. Christ-Crain,et al.  Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. , 2006, American journal of respiratory and critical care medicine.

[28]  Patrick Nicolas,et al.  Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis , 2006, Critical care medicine.

[29]  Mark C Simmonds,et al.  Meta-analysis of individual patient data from randomized trials: a review of methods used in practice , 2005, Clinical trials.

[30]  H. Zulewski,et al.  Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. , 2005, Endocrinology.

[31]  France Gauvin,et al.  Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  J. White,et al.  Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. , 2004, The Journal of clinical endocrinology and metabolism.

[33]  M. Christ-Crain,et al.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial , 2004, The Lancet.

[34]  K. Becker,et al.  In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. , 2003, Endocrinology.

[35]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[36]  A. Mantovani,et al.  High circulating levels of the IL‐1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration , 2002, Journal of leukocyte biology.

[37]  Jonathan A C Sterne,et al.  Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. , 2001, BMJ.

[38]  M. Cetron,et al.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. , 2000, The New England journal of medicine.

[39]  C. Gogos,et al.  Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. , 2000, The Journal of infectious diseases.

[40]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.